Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd + rilvegostomig versus standard of care after surgery for stage I adenocarcinoma NSCLC
NL-OMON60500Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Dato-DXd + rilvegostomig with Standard of care (2 arms). Primary endpoint: Disease-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
datopotamab deruxtecanrilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on NL-OMON60500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60500.